EyeGate Pharmaceuticals reported it did not recognize any revenue for the second quarter of 2019, according to a press release.
In 2018 and the first quarter of 2019, all revenue was attributed to milestone payments from Bausch Health.
Research and development expenses decreased from $1.838 million a year ago to $0.764 million as a result of decreases in activity related to EGP-437 (dexamethasone phosphate), personnel costs, and manufacturing work and market research costs related to the Ocular Bandage Gel (hyaluronic acid).
General and administrative expenses were $1.106 million in the second
Uncategorized